We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+12.21%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$53.1B
AUM Growth
+$4.7B
(+9.7%)
Cap. Flow
-$415M
Cap. Flow
% of AUM
-0.78%
Top 10 Holdings %
Top 10 Hldgs %
15.39%
Holding
2,495
New
186
Increased
937
Reduced
1,188
Closed
172
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$144M |
| 2 |
NVIDIA
NVDA
|
+$137M |
| 3 |
GE Aerospace
GE
|
+$129M |
| 4 |
Dell
DELL
|
+$91.3M |
| 5 |
Comcast
CMCSA
|
+$88.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$103M |
| 2 |
Microchip Technology
MCHP
|
+$98.3M |
| 3 |
Steel Dynamics
STLD
|
+$87M |
| 4 |
UnitedHealth
UNH
|
+$79.5M |
| 5 |
Walmart Inc
WMT
|
+$79.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.58% |
| 2 | Consumer Discretionary | 13.58% |
| 3 | Healthcare | 12.97% |
| 4 | Financials | 12.15% |
| 5 | Industrials | 12.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2301
Heron Therapeutics
HRTX
$63.4M
| $62.7K | ﹤0.01% |
36,855
-85,912
| -70% | -$94.6K |
|
2302
Brookdale Senior Living
BKD
$3.27B
| $61.4K | ﹤0.01% |
+10,556
| New | +$49.5K |
|
2303
Cue Biopharma
CUE
$110M
| $59K | ﹤0.01% |
745
-51
| -6% | -$3.65K |
|
2304
Accuray
ARAY
$34.9M
| $58.9K | ﹤0.01% |
20,798
-2,128
| -9% | -$5.81K |
|
2305
Lyell Immunopharma
LYEL
$351M
| $58.7K | ﹤0.01% |
1,512
+33
| +2% | +$1.19K |
|
2306
Payoneer
PAYO
$2.4B
| $58.3K | ﹤0.01% |
11,187
-9,621
| -46% | -$53K |
|
2307
Sight Sciences
SGHT
$424M
| $56.5K | ﹤0.01% |
+10,950
| New | +$33.8K |
|
2308
Wave Life Sciences
WVE
$1.2B
| $56.4K | ﹤0.01% |
11,168
+95
| +0.9% | +$508 |
|
2309
Advantage Solutions
ADV
$383M
| $50.3K | ﹤0.01% |
+556
| New | +$39.5K |
|
2310
NextNav
NN
$2.11B
| $47.5K | ﹤0.01% |
+10,665
| New | +$48.2K |
|
2311
NuScale Power
SMR
$3.77B
| $47K | ﹤0.01% |
+14,301
| New | +$50.8K |
|
2312
Cerus
CERS
$508M
| $46.8K | ﹤0.01% |
21,666
-297,989
| -93% | -$491K |
|
2313
Seres Therapeutics
MCRB
$50.2M
| $38.7K | ﹤0.01% |
1,383
+631
| +84% | +$16.6K |
|
|
AKTS
2314
DELISTED
Akoustis Technologies Inc
AKTS
| $32.5K | ﹤0.01% |
+38,958
| New | +$26.2K |
|
2315
Douglas Elliman
DOUG
$166M
| $32.4K | ﹤0.01% |
10,990
-14,690
| -57% | -$30.8K |
|
2316
Cadiz
CDZI
$279M
| $30.4K | ﹤0.01% |
10,859
| – | – |
|
2317
Microvast
MVST
$291M
| $15.1K | ﹤0.01% |
10,804
-28,181
| -72% | -$37.8K |
|
|
ME
2318
DELISTED
23andMe Holding Co
ME
| $14K | ﹤0.01% |
768
-89
| -10% | -$1.54K |
|
|
RBOT
2319
DELISTED
Vicarious Surgical
RBOT
| $9.2K | ﹤0.01% |
836
+475
| +132% | +$5.29K |
|
|
GOEV
2320
DELISTED
Canoo Inc. Class A Common Stock
GOEV
| $3.68K | ﹤0.01% |
31
-1
| -3% | -$135 |
|
|
CRGE
2321
DELISTED
Charge Enterprises, Inc. Common Stock
CRGE
| $1.16K | ﹤0.01% |
10,122
-4,823
| -32% | -$1.31K |
|
2322
Arbutus Biopharma
ABUS
$907M
| – | – |
-40,598
| Closed | -$82.4K |
|
2323
Adicet Bio
ACET
$75.9M
| – | – |
-4,689
| Closed | -$103K |
|
2324
Adtran
ADTN
$622M
| – | – |
-23,845
| Closed | -$196K |
|
2325
AGNC Investment
AGNC
$12.8B
| – | – |
-17,835
| Closed | -$168K |
|
Similar funds
VGA
AQR Capital Management's Q4 2023 Portfolio in Review
As of Q4 2023, AQR Capital Management held 2,495 positions worth $53.1B, up 9.7% from $48.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
AQR Capital Management's Q4 2023 filing shows 186 new, 937 increased, 1,188 reduced and 172 closed positions. Its largest new stake was NCR Atleos: 518,383 shares worth $12.5M. The largest sale was Pfizer, an estimated $103M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 23% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- AQR Capital Management's largest Q4 2023 buy was NCR Atleos: 518,383 shares worth $12.5M.
- AQR Capital Management added most to Amazon in Q4 2023, an estimated $144M increase.
- AQR Capital Management's biggest Q4 2023 reduction was Pfizer, cutting an estimated $103M.
- AQR Capital Management fully exited Activision Blizzard in Q4 2023, selling an estimated $38.5M.
- AQR Capital Management's ten largest holdings make up 15% of its $53.1B portfolio in Q4 2023.
- AQR Capital Management opened 186 new positions and closed 172 in Q4 2023.
- AQR Capital Management's portfolio value rose 9.7% quarter-over-quarter to $53.1B.
Based on AQR Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.